HONG KONG, October 30, 2022 /PRNewswire/ — Akeso, Biopharma (9926.HK) (“Akeso”) announced phase Ib clinical results of ivonescimab (PD-1/VEGF bispecific, AK112) in combination with etoposide and carboplatin in the first-line treatment of small cell lung cancer in the Extended Stage (ES-SCLC) in an Oral Presentation at the IASLC 2022 Asia Conference on Lung Cancer.
Preliminary data of the AK112 combination with etoposide and carboplatin showed a favorable safety profile and promising anti-tumor efficacy as a first-line treatment in patients with ES-SCLC and may represent a promising treatment option. Compared to data from marketed PD-L1 inhibitors in combination with chemotherapy, AK112 in combination with chemotherapy demonstrated superior antitumor efficacy and survival benefit.
away June 1, 2022all patients had received at least one dose of AK112. The median follow-up time was 7.2 months.
- The median progression-free survival (PFS) was 6.9 months, with a 6-month PFS rate of 52.1%,
- The objective remission rate (ORR) was 87.5% and the disease control rate (DCR) was 96.9%.
- Overall survival (OS) data are immature.
- No new safety signal was observed.
Lung cancer is one of the most common types of cancer worldwide and in Germany China, with up to two-thirds of SCLC patients having ES-SCLC at initial diagnosis, and etoposide + platinum has been the standard of care for first-line treatment of ES-SCLC for more than 30 years. Two PD-L1 inhibitors have been approved for the treatment of ES-SCLC in combination with chemotherapy, but the survival benefit for patients remains very limited.
Two phase III trials of ivonescimab are being efficiently conducted in key lung cancer indications, including ivonescimab plus chemotherapy versus chemotherapy in advanced non-EGFR squamous cell carcinoma NSCLC that has failed prior EGFR-TKI therapy, and ivonescimab monotherapy versus pembrolizumab monotherapy as initial treatment. Line treatment for NSCLC patients with positive PD-L1 expression.
Related Studies:
Atelelizumab (PD-L1) in combination with…
